IBA develops Streptamer technology:
This article was originally published in Clinica
Executive Summary
German biotech company IBA has developed jointly with the Technical University in Munich, a Streptamer technology - a novel method to functionally isolate and characterise antigen-specific T-cells. Streptamers enable, for the first time, a reversible, antigen-specific staining of T-cells leaving the isolated T-cells phenotypically and functionally indistinguishable from untreated cells, says the Gottingen company. "We believe that our Streptamer technology will have a significant impact on immunological research and the development of T-cell-based therapeutics and diagnostics," said Dr Lothar Germeroth, IBA's CEO.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.